Picard Medical
Provides total artificial heart systems and external drivers for bridge-to-transplant care.
Something off on this page? Send us feedback.
Profile
Sells the SynCardia Total Artificial Heart and external drivers to transplant centers, earning mainly from implant kits plus driver rentals, training, and certification. Commercial activity centers on a single bridge-to-transplant platform approved in the United States and Canada.
Produces the SynCardia Total Artificial Heart, a biventricular replacement approved in the United States and Canada as a bridge to transplant for patients with end-stage biventricular heart failure. Hospitals and transplant centers purchase implant kits; the company also rents the Freedom Driver for discharged patients and provides center training and certification.
Operates a direct North American sales and clinical-support team alongside international distributors, while manufacturing implants and drivers in Tucson. Its commercial platform combines approved implants with external pneumatic drivers, and it is developing the Emperor electromechanical architecture and driver upgrades. Revenue depends on transplant-center adoption, training, reimbursement, regulated manufacturing, and the approval status of the single platform.
Company facts
Key statistics
Year to date −90.6% · Average volume (30d) 2.6M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q2 FY26 | −$1.50 | −$3.05 | −103.3% | $1.6M | $3.0M | +90.6% | +1.54% |
| May 15, 2026Q1 FY26 | −$5.00 | −$5.00 | 0.0% | $1.2M | $1.2M | 0.0% | +7.12% |
| Mar 25, 2026Q4 FY25 | — | −$0.06 | — | — | $1.0M | — | −0.98% |
| Nov 14, 2025Q3 FY25 | — | −$0.19 | — | — | $1.2M | — | −3.70% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $620.0K | $2.1M | $1.2M | $1.0M | $1.2M | $3.0M | |
| Gross profit | −$358.0K | −$127.0K | −$130.0K | $815.0K | $275.0K | $616.0K | |
| Operating income | −$3.2M | −$3.5M | −$3.5M | −$2.5M | −$4.5M | −$4.6M | |
| Net income | −$5.6M | −$7.5M | −$10.4M | −$4.3M | −$7.6M | −$5.7M | |
| Diluted EPS | −$4.40 | −$5.00 | −$9.50 | −$2.91 | −$5.00 | −$3.05 | |
| Gross margin | -57.7% | -6.0% | -11.0% | 80.8% | 23.9% | 20.9% | |
| Operating margin | -523.5% | -165.2% | -293.8% | -252.3% | -392.3% | -156.7% |
Fiscal years (4-quarter sums)FY24 $4.4M · FY25 $4.9M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $38.0K · Total debt $878.0K · Total assets $9.2M · Shareholders' equity $1.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.06M · Float 1.14M · 55.1% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Abbott
Durable LVAD alternative in bridge-to-transplant support.
- Johnson & Johnson
Temporary percutaneous support in acute heart-failure care.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Picard Medical | $8.60 | +0.13% | $18.1M | — | — | 2.9 | +38.6% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 33.6 | 20.9 | 5.4 | +9.8% |